Pfizer Ltd

{"amount":35}

{"amount":100}

{"amount":30}

{"actualRevenue":6450300000,"estimateRevenue":5786000000,"revenueSurprise":664300000,"revenueSurprisePercent":11.4811614241272,"actualEPS":40.42,"estimateEPS":36.966,"surprise":3.454000000000001,"surprisePercent":9.34372125737164}

{"actualRevenue":6292300000,"estimateRevenue":6429000000,"revenueSurprise":-136700000,"revenueSurprisePercent":-2.126302690931716,"actualEPS":41.7,"estimateEPS":40.905,"surprise":0.7950000000000017,"surprisePercent":1.943527686101947}

{"description":"Pfizer Ltd shares surged over 10% on February 10, 2026, following strong Q3FY26 results with a 20% revenue increase and improved margins at 35.4%. Net profit rose 13% year-on-year, driven by key brands like Prevenar 13 and Eliquis. The stock reached an intraday high of ₹5,257.","url":"https://www.cnbctv18.com/market/stocks/pfizer-share-price-jump-over-10-q3-profit-margin-expands-35-pc-ws-l-19846371.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Pfizer's shares surged 11.2% following the release of its Q3FY26 results, showing an 11% YoY increase in net profit to ₹141.84 crore and a 19.8% rise in revenue to ₹645.03 crore. The company also launched a new migraine treatment, Rimegepant ODT, in December 2025.","url":"https://www.business-standard.com/markets/news/pfizer-shares-jump-11-percent-on-posting-healthy-q3-show-pat-up-11-percent-yoy-rev-20-percent-126021000345_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Pfizer Ltd reported strong Q3 results on February 9, 2026, with a net profit increase of 11.1% YoY to ₹141.8 crore and revenue growth of 19.9% YoY to ₹645 crore. EBITDA surged 55.8% YoY, leading to improved operating margins of 35.4%.","url":"https://www.cnbctv18.com/market/pfizer-q3-results-profit-margin-surge-on-strong-revenue-growth-ebitda-up-ws-l-19846048.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Pfizer shares rose 3.95% following a study published in the New England Journal of Medicine, which revealed that its new mRNA flu vaccine outperformed traditional vaccines in a Phase 3 trial involving healthy adults aged 18-64 across multiple countries.","url":"https://www.benzinga.com/trading-ideas/movers/25/11/49014740/why-are-shares-of-pfizer-up-today","sentiment":"Positive","domain":"Benzinga"}

{"description":"Pfizer has made a significant move into the weight-loss drug sector with a $10 billion acquisition of Metsera, aiming to capture a share of the projected $150-200 billion market. The CEO emphasizes the company's competitive potential in this booming industry.","url":"https://www.msn.com/en-us/money/companies/pfizer-ceo-vows-company-will-be-a-formidable-competitor-in-booming-weight-loss-market-after-10b-buy/ar-AA1QnYy6?ocid=BingNewsVerp","sentiment":"Positive","domain":"Fox Business on MSN"}